{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:14:07Z","timestamp":1793733247815,"version":"4.6.1"},"reference-count":209,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T00:00:00Z","timestamp":1639526400000},"content-version":"am","delay-in-days":317,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001602","name":"Science Foundation Ireland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001602","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-20-COVI-0093-COVIMUNE"],"award-info":[{"award-number":["ANR-20-COVI-0093-COVIMUNE"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002081","name":"Irish Research Council","doi-asserted-by":"publisher","award":["GOIPD\/2017\/1283"],"award-info":[{"award-number":["GOIPD\/2017\/1283"]}],"id":[{"id":"10.13039\/501100002081","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["13\/RC\/2073"],"award-info":[{"award-number":["13\/RC\/2073"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nano Today"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.nantod.2020.101051","type":"journal-article","created":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T13:57:02Z","timestamp":1607090222000},"page":"101051","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"special_numbering":"C","title":["Potential immuno-nanomedicine strategies to fight COVID-19 like pulmonary infections"],"prefix":"10.1016","volume":"36","author":[{"given":"Srinivasa Reddy","family":"Bonam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niranjan G.","family":"Kotla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghvendra A.","family":"Bohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yury","family":"Rochev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Webster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0498-9808","authenticated-orcid":false,"given":"Jagadeesh","family":"Bayry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nantod.2020.101051_bib1","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1152\/physrev.00013.2020","article-title":"Elevated plasmin(ogen) as a common risk factor for COVID-19 susceptibility","volume":"100","author":"Ji","year":"2020","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.nantod.2020.101051_bib2","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S2213-2600(20)30076-X","article-title":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome","volume":"8","author":"Xu","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.nantod.2020.101051_bib3","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.nantod.2020.101051_bib4","article-title":"Clinical characteristics of 82 cases of death from COVID-19","volume":"15","author":"Zhang","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.nantod.2020.101051_bib5","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1007\/s00134-020-05991-x","article-title":"Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China","volume":"46","author":"Ruan","year":"2020","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.nantod.2020.101051_bib6","unstructured":"WHO, http:\/\/www.euro.who.int\/en\/health-topics\/health-emergencies\/coronavirus-covid-19\/news\/news\/2020\/3\/who-announces-covid-19-outbreak-a-pandemic, 2020."},{"key":"10.1016\/j.nantod.2020.101051_bib7","doi-asserted-by":"crossref","first-page":"979","DOI":"10.3390\/v11110979","article-title":"Viral metagenomics revealed sendai virus and coronavirus infection of Malayan Pangolins (Manis javanica)","volume":"11","author":"Liu","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.nantod.2020.101051_bib8","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/d41586-020-01692-z","article-title":"Why children avoid the worst coronavirus complications might lie in their arteries","volume":"582","author":"Cyranoski","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.nantod.2020.101051_bib9","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41575-020-0295-7","article-title":"COVID-19: faecal\u2013oral transmission","volume":"17","author":"Hindson","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.nantod.2020.101051_bib10","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1126\/science.abb7269","article-title":"A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV","volume":"368","author":"Yuan","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.nantod.2020.101051_bib11","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00127-20","article-title":"Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus","volume":"94","author":"Wan","year":"2020","journal-title":"J. Virol."},{"key":"10.1016\/j.nantod.2020.101051_bib12","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.nantod.2020.101051_bib13","doi-asserted-by":"crossref","unstructured":"T. Meng, H. Cao, H. Zhang, Z. Kang, D. Xu, H. Gong, et al., bioRxiv, 2020, 2020.2002.2008.926006, https:\/\/doi.org\/10.1101\/2020.02.08.926006.","DOI":"10.1101\/2020.02.08.926006"},{"key":"10.1016\/j.nantod.2020.101051_bib14","doi-asserted-by":"crossref","first-page":"14614","DOI":"10.1128\/JVI.79.23.14614-14621.2005","article-title":"ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia","volume":"79","author":"Jia","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.nantod.2020.101051_bib15","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/path.1570","article-title":"Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis","volume":"203","author":"Hamming","year":"2004","journal-title":"J. Pathol."},{"key":"10.1016\/j.nantod.2020.101051_bib16","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/s41591-020-0868-6","article-title":"SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together withinnate immune genes","volume":"26","author":"Sungnak","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.nantod.2020.101051_bib17","doi-asserted-by":"crossref","unstructured":"A. Sinjab, W. Treekitkarnmongkol, P. Brennan, K. Hara, K. Chang, et al., bioRxiv, 2020, 2020.2004.2016.045617, https:\/\/doi.org\/10.1101\/2020.04.16.045617.","DOI":"10.1101\/2020.04.16.045617"},{"key":"10.1016\/j.nantod.2020.101051_bib18","doi-asserted-by":"crossref","unstructured":"M. Zhong, B.-P. Lin, H.-B. Gao, A.J. Young, X.-H. Wang, C. Liu, et al., bioRxiv, 2020, 2020.2004.2018.047951, https:\/\/doi.org\/10.1101\/2020.04.18.047951.","DOI":"10.1101\/2020.04.18.047951"},{"key":"10.1016\/j.nantod.2020.101051_bib19","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1164\/rccm.202001-0179LE","article-title":"Single-Cell RNA Expression Profiling of ACE2, the Receptor of SARS-CoV-2","volume":"202","author":"Zhao","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.nantod.2020.101051_bib20","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41368-020-0074-x","article-title":"High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa","volume":"12","author":"Xu","year":"2020","journal-title":"Int. J. Oral Sci."},{"key":"10.1016\/j.nantod.2020.101051_bib21","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/d41586-020-01221-y","article-title":"The race for coronavirus vaccines: a graphical guide","volume":"580","author":"Callaway","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.nantod.2020.101051_bib22","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1136\/jclinpath-2020-206522","article-title":"Autopsy in suspected COVID-19 cases","volume":"73","author":"Hanley","year":"2020","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.nantod.2020.101051_bib23","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.7150\/ijbs.45134","article-title":"COVID-19: what has been learned and to be learned about the novel coronavirus disease","volume":"16","author":"Yi","year":"2020","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.nantod.2020.101051_bib24","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1080\/22221751.2020.1746199","article-title":"Hypothesis for potential pathogenesis of SARS-CoV-2 infection\u2013a review of immune changes in patients with viral pneumonia","volume":"9","author":"Lin","year":"2020","journal-title":"Emerg. Microbes & Infect."},{"key":"10.1016\/j.nantod.2020.101051_bib25","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jmii.2020.02.001","article-title":"Emerging threats from zoonotic coronaviruses-from SARS and MERS to 2019-nCoV","volume":"53","author":"Lee","year":"2020","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"10.1016\/j.nantod.2020.101051_bib26","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.diii.2020.03.014","article-title":"COVID-19 pneumonia: a review of typical CT findings and differential diagnosis","volume":"101","author":"Hani","year":"2020","journal-title":"Diagn. Interv. Imaging"},{"key":"10.1016\/j.nantod.2020.101051_bib27","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/jth.14817","article-title":"Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy","volume":"18","author":"Tang","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.nantod.2020.101051_bib28","doi-asserted-by":"crossref","unstructured":"E.M. Negri, B. Piloto, L.K. Morinaga, C.V.P. Jardim, S.A.E.-D. Lamy, M.A. Ferreira, et al., medRxiv, 2020, 2020.2004.2015.20067017, https:\/\/doi.org\/10.1101\/2020.04.15.20067017.","DOI":"10.1101\/2020.04.15.20067017"},{"key":"10.1016\/j.nantod.2020.101051_bib29","doi-asserted-by":"crossref","unstructured":"H.D. Poor, C.E. Ventetuolo, T. Tolbert, G. Chun, G. Serrao, A. Zeidman, et al., medRxiv, 2020, 2020.2004.2017.20057125, https:\/\/doi.org\/10.1101\/2020.04.17.20057125.","DOI":"10.1101\/2020.04.17.20057125"},{"key":"10.1016\/j.nantod.2020.101051_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.00870","volume":"11","author":"Narasaraju","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.nantod.2020.101051_bib31","doi-asserted-by":"crossref","first-page":"L3","DOI":"10.1152\/ajplung.00405.2003","article-title":"Chemokines in acute respiratory distress syndrome","volume":"288","author":"Puneet","year":"2005","journal-title":"Am. J. Physiol.-Lung Cell. Mol. Physiol."},{"key":"10.1016\/j.nantod.2020.101051_bib32","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1465-9921-7-97","article-title":"Lung epithelium as a sentinel and effector system in pneumonia \u2013 molecular mechanisms of pathogen recognition and signal transduction","volume":"7","author":"Hippenstiel","year":"2006","journal-title":"Respir. Res."},{"key":"10.1016\/j.nantod.2020.101051_bib33","doi-asserted-by":"crossref","first-page":"463","DOI":"10.4049\/jimmunol.178.1.463","article-title":"Differential regulation of cytokine release and leukocyte migration by lipopolysaccharide-stimulated primary human lung alveolar type ii epithelial cells and macrophages","volume":"178","author":"Thorley","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.nantod.2020.101051_bib34","doi-asserted-by":"crossref","unstructured":"S. Tian, W. Hu, L. Niu, H. Liu, H. Xu, S.-Y. Xiao, Preprints, 2020, https:\/\/doi.org\/10.20944\/preprints202002.0220.v1","DOI":"10.20944\/preprints202002.0220.v1"},{"key":"10.1016\/j.nantod.2020.101051_bib35","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/labinvest.3700440","article-title":"Mechanical ventilation induces inflammation, lung injury, and extra-pulmonary organ dysfunction in experimental pneumonia","volume":"86","author":"Dhanireddy","year":"2006","journal-title":"Lab. Investig."},{"key":"10.1016\/j.nantod.2020.101051_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102763","article-title":"Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients","volume":"55","author":"Liu","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.nantod.2020.101051_bib37","doi-asserted-by":"crossref","first-page":"eabd2071","DOI":"10.1126\/sciimmunol.abd2071","article-title":"Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome","volume":"5","author":"Weiskopf","year":"2020","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.nantod.2020.101051_bib38","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41590-019-0585-9","article-title":"Diversity at the border","volume":"21","author":"Zemans","year":"2020","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.nantod.2020.101051_bib39","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41572-019-0069-0","article-title":"Acute respiratory distress syndrome","volume":"5","author":"Matthay","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.nantod.2020.101051_bib40","doi-asserted-by":"crossref","unstructured":"G. Li, S.E. Fox, B. Summa, B. Hu, C. Wenk, A. Akmatbekov, et al., bioRxiv, 2020, 2020.2004.2011.037473, https:\/\/doi.org\/10.1101\/2020.04.11.037473.","DOI":"10.1101\/2020.04.11.037473"},{"key":"10.1016\/j.nantod.2020.101051_bib41","doi-asserted-by":"crossref","first-page":"508","DOI":"10.4049\/jimmunol.1001002","article-title":"CCR2-antagonist prophylaxis reduces pulmonary immune pathology and markedly improves survival during influenza infection","volume":"186","author":"Lin","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.nantod.2020.101051_bib42","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41577-019-0167-y","article-title":"How macrophages deal with death","volume":"19","author":"Lemke","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.nantod.2020.101051_bib43","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1093\/infdis\/jiv380","article-title":"Middle east respiratory syndrome coronavirus efficiently infects human primary T lymphocytes and activates the extrinsic and intrinsic apoptosis pathways","volume":"213","author":"Chu","year":"2016","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.nantod.2020.101051_bib44","doi-asserted-by":"crossref","unstructured":"Y. chen, Z. Feng, B. Diao, R. Wang, G. Wang, C. Wang, et al., medRxiv, 2020, 2020.2003.2027.20045427, https:\/\/doi.org\/10.1101\/2020.03.27.20045427.","DOI":"10.1101\/2020.03.27.20045427"},{"key":"10.1016\/j.nantod.2020.101051_bib45","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.ijid.2020.05.055","article-title":"Association of inflammatory markers with the severity of COVID-19: a meta-analysis","volume":"96","author":"Zeng","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.nantod.2020.101051_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102537","article-title":"The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease","volume":"19","author":"McGonagle","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.nantod.2020.101051_bib47","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3389\/fimmu.2020.00827","article-title":"Reduction and functional exhaustion of t cells in patients with coronavirus disease 2019 (COVID-19)","volume":"11","author":"Diao","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.nantod.2020.101051_bib48","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.alit.2016.05.006","article-title":"Toll-like receptor 3 ligand specifically induced bronchial epithelial cell death in caspase dependent manner and functionally upregulated Fas expression","volume":"65 Suppl","author":"Koizumi","year":"2016","journal-title":"Allergol. Int."},{"key":"10.1016\/j.nantod.2020.101051_bib49","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.drudis.2020.01.015","article-title":"Recent discovery and development of inhibitors targeting coronaviruses","volume":"25","author":"Pillaiyar","year":"2020","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.nantod.2020.101051_bib50","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.drudis.2020.03.019","article-title":"D\u00e9j\u00e0 vu: stimulating open drug discovery for SARS-CoV-2","volume":"25","author":"Ekins","year":"2020","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.nantod.2020.101051_bib51","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s11427-020-1637-5","article-title":"Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission","volume":"63","author":"Xu","year":"2020","journal-title":"Sci. China Life Sci."},{"key":"10.1016\/j.nantod.2020.101051_bib52","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s00134-020-05985-9","article-title":"Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target","volume":"46","author":"Zhang","year":"2020","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.nantod.2020.101051_bib53","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.nantod.2020.101051_bib54","article-title":"Protein structure analysis of the interactions between SARS-CoV-2 spike protein and the human ACE2 receptor: from conformational changes to novel neutralizing antibodies","author":"Mercurio","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.nantod.2020.101051_bib55","doi-asserted-by":"crossref","first-page":"8904","DOI":"10.1074\/jbc.M111.325803","article-title":"Mechanisms of host receptor adaptation by severe acute respiratory syndrome coronavirus","volume":"287","author":"Wu","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nantod.2020.101051_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104742","article-title":"The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade","volume":"176","author":"Coutard","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.nantod.2020.101051_bib57","unstructured":"W. Canrong, Y. Yueying, L. Yang, Z. Peng, W. Yali, W. Qiqi, et al., chinaXiv, \u3008https:\/\/doi.org\/10.12074\/202002.00062\u3009."},{"key":"10.1016\/j.nantod.2020.101051_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117592","article-title":"Ribavirin, remdesivir, sofosbuvir, galidesivir, and tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study","volume":"253","author":"Elfiky","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.nantod.2020.101051_bib59","doi-asserted-by":"crossref","unstructured":"D.E. Gordon, G.M. Jang, M. Bouhaddou, J. Xu, K. Obernier, M.J. O'Meara, et al., bioRxiv, 2020, 2020.2003.2022.002386, https:\/\/doi.org\/10.1101\/2020.03.22.002386.","DOI":"10.1101\/2020.03.22.002386"},{"key":"10.1016\/j.nantod.2020.101051_bib60","doi-asserted-by":"crossref","unstructured":"C. Ma, M.D. Sacco, B. Hurst, J.A. Townsend, Y. Hu, T. Szeto, et al., bioRxiv (2020) 2020.2004.2020.051581, https:\/\/doi.org\/10.1101\/2020.04.20.051581.","DOI":"10.1101\/2020.04.20.051581"},{"key":"10.1016\/j.nantod.2020.101051_bib61","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.chom.2016.01.007","article-title":"Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice","volume":"19","author":"Channappanavar","year":"2016","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.nantod.2020.101051_bib62","doi-asserted-by":"crossref","first-page":"E4251","DOI":"10.1073\/pnas.1618310114","article-title":"Coronavirus nonstructural protein 15 mediates evasion of dsRNA sensors and limits apoptosis in macrophages","volume":"114","author":"Deng","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.nantod.2020.101051_bib63","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.molimm.2019.07.003","article-title":"Porcine deltacoronavirus nsp15 antagonizes interferon-\u03b2 production independently of its endoribonuclease activity","volume":"114","author":"Liu","year":"2019","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.nantod.2020.101051_bib64","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.cell.2020.04.011","article-title":"The architecture of SARS-CoV-2 transcriptome","volume":"181","author":"Kim","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.nantod.2020.101051_bib65","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/s41577-020-0312-7","article-title":"COVID-19: risk for cytokine targeting in chronic inflammatory diseases","volume":"20","author":"Schett","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.nantod.2020.101051_bib66","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s41584-020-0448-7","article-title":"Autoimmune and inflammatory diseases following COVID-19","volume":"16","author":"Galeotti","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.nantod.2020.101051_bib67","article-title":"Adjunct immunotherapies for the management of severely Ill COVID-19 patients","volume":"1","author":"Bonam","year":"2020","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.nantod.2020.101051_bib68","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02182-2020","article-title":"Potential of regulatory T-cell-based therapies in the management of severe COVID-19","volume":"56","author":"Stephen-Victor","year":"2020","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.nantod.2020.101051_bib69","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.coph.2006.03.001","article-title":"Angiotensin-converting enzyme 2 in lung diseases","volume":"6","author":"Kuba","year":"2006","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.nantod.2020.101051_bib70","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1080\/22221751.2020.1746200","article-title":"Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension","volume":"9","author":"Meng","year":"2020","journal-title":"Emerg. Microbes & Infect."},{"key":"10.1016\/j.nantod.2020.101051_bib71","doi-asserted-by":"crossref","unstructured":"M. Zhong, A. Sun, T. Xiao, G. Yao, L. Sang, X. Zheng, et al., medRxiv, 2020, 2020.2004.2015.20066266, https:\/\/doi.org\/10.1101\/2020.04.15.20066266.","DOI":"10.1101\/2020.04.15.20066266"},{"key":"10.1016\/j.nantod.2020.101051_bib72","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.tips.2020.03.006","article-title":"Ongoing clinical trials for the management of the COVID-19 pandemic","volume":"41","author":"Lythgoe","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.nantod.2020.101051_bib73","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1089\/jamp.2009.0775","article-title":"Acute lung injury: epidemiology, pathogenesis, and treatment","volume":"23","author":"Johnson","year":"2010","journal-title":"J. Aerosol. Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.nantod.2020.101051_bib74","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMoa050333","article-title":"Incidence and outcomes of acute lung injury","volume":"353","author":"Rubenfeld","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.nantod.2020.101051_bib75","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1513\/pats.200708-141DR","article-title":"Treatment of acute lung injury: clinical and experimental studies","volume":"5","author":"Matthay","year":"2008","journal-title":"Proc. Am. Thorac. Soc."},{"key":"10.1016\/j.nantod.2020.101051_bib76","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1001\/jama.2017.21907","article-title":"Acute respiratory distress syndrome: advances in diagnosis and treatment","volume":"319","author":"Fan","year":"2018","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.nantod.2020.101051_bib77","first-page":"742","volume":"42","author":"Ventola","year":"2017","journal-title":"P & T Peer-rev. J. Formul. Manag."},{"key":"10.1016\/j.nantod.2020.101051_bib78","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil\u00ae \u2014 The first FDA-approved nano-drug: lessons learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.nantod.2020.101051_bib79","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2119\/molmed.2013.00165","article-title":"Molecular mechanisms of pulmonary arterial remodeling","volume":"20","author":"Crosswhite","year":"2014","journal-title":"Mol. Med."},{"key":"10.1016\/j.nantod.2020.101051_bib80","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/17425247.2017.1360863","article-title":"Nanomedicine formulations for the delivery of antiviral drugs: a promising solution for the treatment of viral infections","volume":"15","author":"Lembo","year":"2018","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.nantod.2020.101051_bib81","first-page":"105","article-title":"The role of nanotechnology in the treatment of viral infections","volume":"4","author":"Singh","year":"2017","journal-title":"Ther. Adv. Infect. Dis"},{"key":"10.1016\/j.nantod.2020.101051_bib82","doi-asserted-by":"crossref","first-page":"4369","DOI":"10.1021\/acsami.7b13811","article-title":"Glutathione-capped Ag2S nanoclusters inhibit coronavirus proliferation through blockage of viral RNA synthesis and budding","volume":"10","author":"Du","year":"2018","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.nantod.2020.101051_bib83","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.coviro.2013.02.004","article-title":"Intervention strategies for emerging respiratory virus infections: policy and public health considerations","volume":"3","author":"Nguyen-Van-Tam","year":"2013","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.nantod.2020.101051_bib84","doi-asserted-by":"crossref","first-page":"89","DOI":"10.4103\/0975-7406.76478","article-title":"Mucoadhesive drug delivery systems","volume":"3","author":"Shaikh","year":"2011","journal-title":"J. Pharm. Bioall. Sci."},{"key":"10.1016\/j.nantod.2020.101051_bib85","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3390\/pharmaceutics12020171","article-title":"Nanomaterials designed for antiviral drug delivery transport across biological barriers","volume":"12","author":"Cojocaru","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.nantod.2020.101051_bib86","unstructured":"\u3008https:\/\/www.swissbiotech.org\/listing\/bioavanta-bosti-announces-immediate-availability-of-its-chitosan-nanoparticle-technology-to-formulate-aerosol-anit-covid-19-drugs\/\u3009, 2020."},{"key":"10.1016\/j.nantod.2020.101051_bib87","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.3390\/md13085156","article-title":"Chitosan: an update on potential biomedical and pharmaceutical applications","volume":"13","author":"Cheung","year":"2015","journal-title":"Mar. Drugs"},{"key":"10.1016\/j.nantod.2020.101051_bib88","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1016\/j.vaccine.2009.05.029","article-title":"Eleven years of Inflexal\u00ae V\u2014a virosomal adjuvanted influenza vaccine","volume":"27","author":"Herzog","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.nantod.2020.101051_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2020.198114","article-title":"COVID-19 vaccine: a comprehensive status report","volume":"288","author":"Kaur","year":"2020","journal-title":"Virus Res."},{"key":"10.1016\/j.nantod.2020.101051_bib90","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41565-020-0732-3","article-title":"Immune-mediated approaches against COVID-19","volume":"15","author":"Florindo","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.nantod.2020.101051_bib91","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41577-020-00434-6","article-title":"Immunological considerations for COVID-19 vaccine strategies","volume":"20","author":"Jeyanathan","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.nantod.2020.101051_bib92","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.tips.2017.06.002","article-title":"An overview of novel adjuvants designed for improving vaccine efficacy","volume":"38","author":"Bonam","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.nantod.2020.101051_bib93","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.02224","article-title":"Nanoparticle vaccines against infectious diseases","volume":"9","author":"Pati","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.nantod.2020.101051_bib94","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/s41565-020-0737-y","article-title":"COVID-19 vaccine development and a potential nanomaterial path forward","volume":"15","author":"Shin","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.nantod.2020.101051_bib95","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.3390\/ijms19113605","article-title":"DNA vaccines\u2014how far from clinical use","volume":"19","author":"Hobernik","year":"2018","journal-title":"Int. J. Mol. ci.S"},{"key":"10.1016\/j.nantod.2020.101051_bib96","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jddst.2015.05.007","article-title":"Oleic acid nanoemulsion for nasal vaccination: impact on adjuvanticity based immune response","volume":"28","author":"Sravanthi","year":"2015","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.nantod.2020.101051_bib97","doi-asserted-by":"crossref","first-page":"eabc9396","DOI":"10.1126\/scitranslmed.abc9396","article-title":"AnAlphavirus-derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates","volume":"12","author":"Erasmus","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.nantod.2020.101051_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2020.101001","article-title":"Exploring the role of triazole functionalized heteroatom co-doped carbon quantum dots against human coronaviruses","volume":"35","author":"Garg","year":"2020","journal-title":"Nano Today"},{"key":"10.1016\/j.nantod.2020.101051_bib99","doi-asserted-by":"crossref","unstructured":"J.-H. Tian, N. Patel, R. Haupt, H. Zhou, S. Weston, H. Hammond, et al., bioRxiv, 2020, 2020.2006.2029.178509, https:\/\/doi.org\/10.1101\/2020.06.29.178509.","DOI":"10.1101\/2020.06.29.178509"},{"key":"10.1016\/j.nantod.2020.101051_bib100","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s12026-018-8991-x","volume":"66","author":"Magnusson","year":"2018","journal-title":"Immunol. Res."},{"key":"10.1016\/j.nantod.2020.101051_bib101","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2026920","article-title":"Phase 1\u20132 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine","author":"Keech","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.nantod.2020.101051_bib102","doi-asserted-by":"crossref","unstructured":"B.K. Haun, C.-Y. Lai, C.A. Williams, T.A. Wong, M.M. Lieberman, L. Pessaint, et al., bioRxiv, 2020, 2020.2007.2024.220715, https:\/\/doi.org\/10.1101\/2020.07.24.220715.","DOI":"10.1101\/2020.07.24.220715"},{"key":"10.1016\/j.nantod.2020.101051_bib103","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jim.2016.09.008","article-title":"CoVaccine HTTM adjuvant is superior to Freund\u2019s adjuvants in eliciting antibodies against the endogenous alarmin HMGB1","volume":"439","author":"Lakhan","year":"2016","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.nantod.2020.101051_bib104","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.3389\/fimmu.2018.02464","article-title":"A recombinant subunit based zika virus vaccine is efficacious in non-human primates","volume":"9","author":"Medina","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.nantod.2020.101051_bib105","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1016\/j.vaccine.2017.01.068","article-title":"Recombinant proteins of Zaire ebolavirus induce potent humoral and cellular immune responses and protect against live virus infection in mice","volume":"36","author":"Lehrer","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.nantod.2020.101051_bib106","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/1475-2875-10-182","article-title":"Safety and immunogenicity of multi-antigen AMA1-based vaccines formulated with CoVaccine HTTM and Montanide ISA 51 in rhesus macaques","volume":"10","author":"Kusi","year":"2011","journal-title":"Malar. J."},{"key":"10.1016\/j.nantod.2020.101051_bib107","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2014352117","article-title":"Decoy nanoparticles protect against COVID-19 by concurrently adsorbing viruses and inflammatory cytokines","author":"Rao","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.nantod.2020.101051_bib108","doi-asserted-by":"crossref","first-page":"6383","DOI":"10.1021\/acsnano.0c03697","article-title":"Toward nanotechnology-enabled approaches against the COVID-19 pandemic","volume":"14","author":"Weiss","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.nantod.2020.101051_bib109","doi-asserted-by":"crossref","first-page":"7760","DOI":"10.1021\/acsnano.0c04006","article-title":"Nanotechnology for COVID-19: therapeutics and vaccine research","volume":"14","author":"Chauhan","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.nantod.2020.101051_bib110","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.2217\/nnm-2020-0117","article-title":"Application of nanomaterials in treatment, anti-infection and detection of coronaviruses","volume":"15","author":"Nikaeen","year":"2020","journal-title":"Nanomedicine"},{"key":"10.1016\/j.nantod.2020.101051_bib111","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.3390\/nano10061072","article-title":"Nanomaterials and nanotechnology-associated innovations against viral infections with a focus on coronaviruses","volume":"10","author":"Nasrollahzadeh","year":"2020","journal-title":"Nanomaterials"},{"key":"10.1016\/j.nantod.2020.101051_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2020.100961","article-title":"Nanomedicine strategies to target coronavirus","volume":"35","author":"Heinrich","year":"2020","journal-title":"Nano Today"},{"key":"10.1016\/j.nantod.2020.101051_bib113","doi-asserted-by":"crossref","unstructured":"C. Wang, S. Wang, Y. Chen, J. Zhao, S. Han, G. Zhao, et al., bioRxiv, 2020, 2020.2008.2012.247338, https:\/\/doi.org\/10.1101\/2020.08.12.247338.","DOI":"10.1101\/2020.08.12.247338"},{"key":"10.1016\/j.nantod.2020.101051_bib114","doi-asserted-by":"crossref","first-page":"7790","DOI":"10.1128\/JVI.01244-13","article-title":"Middle east respiratory syndrome coronavirus (MERS-CoV): announcement of the coronavirus study group","volume":"87","author":"de Groot","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.nantod.2020.101051_bib115","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1056\/NEJMoa1306742","article-title":"Hospital outbreak of middle east respiratory syndrome coronavirus","volume":"369","author":"Assiri","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.nantod.2020.101051_bib116","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1056\/NEJMc1308698","article-title":"Middle east respiratory syndrome coronavirus infections in health care workers","volume":"369","author":"Memish","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.nantod.2020.101051_bib117","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1211721","article-title":"Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia","volume":"367","author":"Zaki","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.nantod.2020.101051_bib118","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S1473-3099(13)70204-4","article-title":"Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study","volume":"13","author":"Assiri","year":"2013","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.nantod.2020.101051_bib119","doi-asserted-by":"crossref","first-page":"19799","DOI":"10.1021\/acsami.9b04240","article-title":"Novel gold nanorod-based HR1 peptide inhibitor for middle east respiratory syndrome coronavirus","volume":"11","author":"Huang","year":"2019","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.nantod.2020.101051_bib120","first-page":"1","article-title":"Can nanotechnology help in the fight against COVID-19?","author":"Palestino","year":"2020","journal-title":"Expert Rev. Anti Infect. Ther"},{"key":"10.1016\/j.nantod.2020.101051_bib121","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/s41565-020-0751-0","article-title":"Nanotechnology-based disinfectants and sensors for SARS-CoV-2","volume":"15","author":"Talebian","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.nantod.2020.101051_bib122","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3390\/pharmaceutics8010006","article-title":"Development of liposomal ciprofloxacin to treat lung infections","volume":"8","author":"Cipolla","year":"2016","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.nantod.2020.101051_bib123","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s40265-019-01095-z","article-title":"Amikacin liposome inhalation suspension: a review in Mycobacterium avium complex lung disease","volume":"79","author":"Shirley","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.nantod.2020.101051_bib124","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1164\/rccm.201604-0700OC","article-title":"Randomized trial of liposomal amikacin for inhalation in nontuberculous mycobacterial lung disease","volume":"195","author":"Olivier","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.nantod.2020.101051_bib125","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/j.vaccine.2017.02.012","article-title":"MERS-CoV spike nanoparticles protect mice from MERS-CoV infection","volume":"35","author":"Coleman","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.nantod.2020.101051_bib126","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0007142","article-title":"Inducible bronchus-associated lymphoid tissue elicited by a protein cage nanoparticle enhances protection in mice against diverse respiratory viruses","volume":"4","author":"Wiley","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.nantod.2020.101051_bib127","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1477-3155-8-22","article-title":"Development of PEGylated PLGA nanoparticle for controlled and sustained drug delivery in cystic fibrosis","volume":"8","author":"Vij","year":"2010","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.nantod.2020.101051_bib128","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41541-020-0170-0","article-title":"The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines","volume":"5","author":"Shang","year":"2020","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.nantod.2020.101051_bib129","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/d41573-020-00151-8","article-title":"Evolution of the COVID-19 vaccine development landscape","volume":"19","author":"Le","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.nantod.2020.101051_bib130","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.carbon.2016.09.032","article-title":"Carbon dots as inhibitors of virus by activation of type I interferon response","volume":"110","author":"Du","year":"2016","journal-title":"Carbon"},{"key":"10.1016\/j.nantod.2020.101051_bib131","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jviromet.2016.12.015","article-title":"Cytotoxicity and antiviral activity of electrochemical \u2013 synthesized silver nanoparticles against poliovirus","volume":"241","author":"Huy","year":"2017","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.nantod.2020.101051_bib132","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13643-020-01343-4","article-title":"Traditional Chinese herbal medicine for treating novel coronavirus (COVID-19) pneumonia: protocol for a systematic review and meta-analysis","volume":"9","author":"Li","year":"2020","journal-title":"Syst. Rev."},{"key":"10.1016\/j.nantod.2020.101051_bib133","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.biotechadv.2008.09.002","article-title":"Silver nanoparticles as a new generation of antimicrobials","volume":"27","author":"Rai","year":"2009","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.nantod.2020.101051_bib134","doi-asserted-by":"crossref","unstructured":"G.C. Tremiliosi, L.G.P. Simoes, D.T. Minozzi, R.I. Santos, D.C.B. Vilela, E.L. Durigon, et al., bioRxiv, 2020, 2020.2006.2026.152520, https:\/\/doi.org\/10.1101\/2020.06.26.152520.","DOI":"10.1101\/2020.06.26.152520"},{"key":"10.1016\/j.nantod.2020.101051_bib135","doi-asserted-by":"crossref","first-page":"28016","DOI":"10.1039\/C7RA03167J","article-title":"Blue and cyan fluorescent carbon dots: one-pot synthesis, selective cell imaging and their antiviral activity","volume":"7","author":"Liu","year":"2017","journal-title":"RSC Adv."},{"key":"10.1016\/j.nantod.2020.101051_bib136","doi-asserted-by":"crossref","first-page":"5451","DOI":"10.1021\/acsanm.8b00779","article-title":"Multisite inhibitors for enteric coronavirus: antiviral cationic carbon dots based on curcumin","volume":"1","author":"Ting","year":"2018","journal-title":"ACS Appl. Nano Mater."},{"key":"10.1016\/j.nantod.2020.101051_bib137","article-title":"A review on antibacterial, antiviral, and antifungal activity of curcumin","volume":"2014","author":"Moghadamtousi","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.nantod.2020.101051_bib138","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s12951-020-00685-4","article-title":"How can nanotechnology help to combat COVID-19? Opportunities and urgent need","volume":"18","author":"Campos","year":"2020","journal-title":"J. Nanobiotechnol"},{"key":"10.1016\/j.nantod.2020.101051_bib139","doi-asserted-by":"crossref","unstructured":"G. Pezzotti, E. Ohgitani, M. Shin-Ya, T. Adachi, E. Marin, F. Boschetto, et al., bioRxiv, 2020, 2020.2006.2019.159970, https:\/\/doi.org\/10.1101\/2020.06.19.159970.","DOI":"10.1101\/2020.06.19.159970"},{"key":"10.1016\/j.nantod.2020.101051_bib140","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1080\/17435390.2020.1786185","article-title":"Nano-safety research lessons for dealing with aerosol transmissions of COVID-19","volume":"14","author":"Riediker","year":"2020","journal-title":"Nanotoxicology"},{"key":"10.1016\/j.nantod.2020.101051_bib141","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1021\/acssensors.9b00175","article-title":"Development of label-free colorimetric assay for MERS-CoV using gold nanoparticles","volume":"4","author":"Kim","year":"2019","journal-title":"ACS Sens."},{"key":"10.1016\/j.nantod.2020.101051_bib142","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.jmii.2020.03.032","article-title":"Lopinavir\/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan","volume":"53","author":"Cheng","year":"2020","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"10.1016\/j.nantod.2020.101051_bib143","article-title":"Azvudine, a novel nucleoside reverse transcriptase inhibitor showed good drug combination features and better inhibition on drug-resistant strains than lamivudine in vitro","volume":"9","author":"Wang","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.nantod.2020.101051_bib144","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jama.2020.1585","article-title":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus\u2013infected pneumonia in Wuhan, China","volume":"323","author":"Wang","year":"2020","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.nantod.2020.101051_bib145","doi-asserted-by":"crossref","first-page":"43395","DOI":"10.1038\/srep43395","article-title":"GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses","volume":"7","author":"Lo","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.nantod.2020.101051_bib146","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature17180","article-title":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys","volume":"531","author":"Warren","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.nantod.2020.101051_bib147","doi-asserted-by":"crossref","first-page":"eaal3653","DOI":"10.1126\/scitranslmed.aal3653","article-title":"Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses","volume":"9","author":"Sheahan","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.nantod.2020.101051_bib148","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/cbic.202000047","article-title":"Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019\u2010nCoV","volume":"21","author":"Morse","year":"2020","journal-title":"ChemBioChem"},{"key":"10.1016\/j.nantod.2020.101051_bib149","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030343","article-title":"SARS: systematic review of treatment effects","volume":"3","author":"Stockman","year":"2006","journal-title":"PLoS Med."},{"key":"10.1016\/j.nantod.2020.101051_bib150","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.1977","article-title":"Clinical outcomes of current medical approaches for Middle East respiratory syndrome: a systematic review and meta-analysis","volume":"28","author":"Morra","year":"2018","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.nantod.2020.101051_bib151","unstructured":"\u3008https:\/\/www.fujifilm.com\/jp\/en\/news\/hq\/3211?_ga=2.98370583.926946726.1587470916\u2013273032141.1587470916\u3009, 2020."},{"key":"10.1016\/j.nantod.2020.101051_bib152","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.antiviral.2014.04.006","article-title":"Arbidol as a broad-spectrum antiviral: an update","volume":"107","author":"Blaising","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.nantod.2020.101051_bib153","doi-asserted-by":"crossref","unstructured":"Q. Liu, X. Fang, L. Tian, X. Chen, U. Chung, K. Wang, et al., medRxiv, 2020, 2020.2004.2011.20056523, https:\/\/doi.org\/10.1101\/2020.04.11.20056523.","DOI":"10.1101\/2020.04.11.20056523"},{"key":"10.1016\/j.nantod.2020.101051_bib154","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.coviro.2019.01.006","article-title":"Baloxavir marboxil: the new influenza drug on the market","volume":"35","author":"O\u2019Hanlon","year":"2019","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.nantod.2020.101051_bib155","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2165\/00063030-200216040-00005","article-title":"Anakinra","volume":"16","author":"Cvetkovic","year":"2002","journal-title":"Biodrugs"},{"key":"10.1016\/j.nantod.2020.101051_bib156","doi-asserted-by":"crossref","first-page":"18951","DOI":"10.1073\/pnas.2009017117","article-title":"Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19","volume":"117","author":"Cauchois","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.nantod.2020.101051_bib157","doi-asserted-by":"crossref","first-page":"e325","DOI":"10.1016\/S2665-9913(20)30127-2","article-title":"Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study","volume":"2","author":"Cavalli","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.nantod.2020.101051_bib158","doi-asserted-by":"crossref","DOI":"10.1172\/JCI141772","article-title":"Baricitinib restrains the immune dysregulation in patients with severe COVID-19","author":"Bronte","year":"2020","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.nantod.2020.101051_bib159","first-page":"ciaa879","article-title":"Use of baricitinib in patients with moderate to severe coronavirus disease 2019","author":"Titanji","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.nantod.2020.101051_bib160","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/03946320140270S103","article-title":"Adalimumab in the treatment of immune-mediated diseases","volume":"27","author":"Lapadula","year":"2014","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"10.1016\/j.nantod.2020.101051_bib161","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1177\/2040620712459746","article-title":"Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians","volume":"3","author":"Harrison","year":"2012","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/j.nantod.2020.101051_bib162","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1634\/theoncologist.2009-0317","article-title":"Bevacizumab","volume":"15","author":"Kazazi-Hyseni","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.nantod.2020.101051_bib163","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/nrd2369","article-title":"Eculizumab","volume":"6","author":"Parker","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.nantod.2020.101051_bib164","doi-asserted-by":"crossref","first-page":"857","DOI":"10.3389\/fphar.2020.00857","article-title":"Combination of Ruxolitinib and Eculizumab for treatment of severe SARS-CoV-2-related acute respiratory distress syndrome: a controlled study","volume":"11","author":"Giudice","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.nantod.2020.101051_bib165","first-page":"4040","article-title":"Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience","volume":"24","author":"Diurno","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci"},{"key":"10.1016\/j.nantod.2020.101051_bib166","doi-asserted-by":"crossref","first-page":"S180","DOI":"10.1016\/j.bbmt.2019.12.741","article-title":"Targeting Danger Associated Molecular Pattern (DAMP) with CD24Fc to reduce acute Gvhd: study design on a randomized double blind placebo controlled Phase III clinical trial (CATHY Study)","volume":"26","author":"Zheng","year":"2020","journal-title":"Biol. Blood Marrow Transpl."},{"key":"10.1016\/j.nantod.2020.101051_bib167","article-title":"The COVID-19 pandemic and the use of MS disease-modifying therapies","volume":"39","author":"Giovannoni","year":"2020","journal-title":"Mult. Scler. Related Disord."},{"key":"10.1016\/j.nantod.2020.101051_bib168","doi-asserted-by":"crossref","unstructured":"Z. Meng, T. Wang, C. Li, X. Chen, L. Li, X. Qin, et al., medRxiv, 2020, 2020.2004.2011.20061473, https:\/\/doi.org\/10.1101\/2020.04.11.20061473.","DOI":"10.1101\/2020.04.11.20061473"},{"key":"10.1016\/j.nantod.2020.101051_bib169","doi-asserted-by":"crossref","unstructured":"H. Bian, Z.-H. Zheng, D. Wei, Z. Zhang, W.-Z. Kang, C.-Q. Hao, et al., medRxiv (2020) 2020.2003.2021.20040691, https:\/\/doi.org\/10.1101\/2020.03.21.20040691.","DOI":"10.1101\/2020.03.21.20040691"},{"key":"10.1016\/j.nantod.2020.101051_bib170","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s40265-019-01167-0","article-title":"Camrelizumab: first global approval","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.nantod.2020.101051_bib171","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3389\/fimmu.2020.00085","article-title":"Citrullination alters the antiviral and immunomodulatory activities of the human cathelicidin LL-37 during rhinovirus infection","volume":"11","author":"Casanova","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.nantod.2020.101051_bib172","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2020.102452","article-title":"Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)","volume":"111","author":"Liu","year":"2020","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.nantod.2020.101051_bib173","doi-asserted-by":"crossref","unstructured":"M. Roumier, R. Paule, M. Groh, A. Vallee, F. Ackermann, medRxiv, 2020, 2020.2004.2020.20061861, https:\/\/doi.org\/10.1101\/2020.04.20.20061861.","DOI":"10.1101\/2020.04.20.20061861"},{"key":"10.1016\/j.nantod.2020.101051_bib174","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2020.102511","article-title":"Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients","author":"Canziani","year":"2020","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.nantod.2020.101051_bib175","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2020.08.024","article-title":"Impact of tocilizumab on mortality and\/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients","author":"Klopfenstein","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.nantod.2020.101051_bib176","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virol.2020.05.006","article-title":"Recovery of severely ill COVID-19 patients by intravenous immunoglobulin (IVIG) treatment: a case series","volume":"548","author":"Mohtadi","year":"2020","journal-title":"Virology"},{"key":"10.1016\/j.nantod.2020.101051_bib177","doi-asserted-by":"crossref","first-page":"ofaa102","DOI":"10.1093\/ofid\/ofaa102","article-title":"High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019","volume":"7","author":"Cao","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.nantod.2020.101051_bib178","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/d41587-020-00011-1","article-title":"Convalescent serum lines up as first-choice treatment for coronavirus","volume":"38","author":"Sheridan","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.nantod.2020.101051_bib179","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 critically Ill patients with COVID-19 with convalescent plasma","volume":"323","author":"Shen","year":"2020","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.nantod.2020.101051_bib180","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2004168117","article-title":"Effectiveness of convalescent plasma therapy in severe COVID-19 patients","author":"Duan","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.nantod.2020.101051_bib181","doi-asserted-by":"crossref","unstructured":"G. Rada, J. Corbalan, P. Rojas, medRxiv, 2020, 2020.2004.2013.20064162, https:\/\/doi.org\/10.1101\/2020.04.13.20064162.","DOI":"10.1101\/2020.04.13.20064162"},{"key":"10.1016\/j.nantod.2020.101051_bib182","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(20)30317-2","article-title":"Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury","volume":"395","author":"Russell","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.nantod.2020.101051_bib183","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/22221751.2020.1747363","article-title":"Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients","volume":"9","author":"Xiong","year":"2020","journal-title":"Emerg. Microbes & Infect."},{"key":"10.1016\/j.nantod.2020.101051_bib184","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1136\/ard.59.11.841","article-title":"Leflunomide: mode of action in the treatment of rheumatoid arthritis","volume":"59","author":"Breedveld","year":"2000","journal-title":"Ann. Rheum. Dis"},{"key":"10.1016\/j.nantod.2020.101051_bib185","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105960","article-title":"Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection","volume":"55","author":"Fantini","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.nantod.2020.101051_bib186","doi-asserted-by":"crossref","first-page":"m1844","DOI":"10.1136\/bmj.m1844","article-title":"Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data","volume":"369","author":"Mah\u00e9vas","year":"2020","journal-title":"Br. Med. J."},{"key":"10.1016\/j.nantod.2020.101051_bib187","doi-asserted-by":"crossref","unstructured":"J. Magagnoli, S. Narendran, F. Pereira, T. Cummings, J.W. Hardin, S.S. Sutton, et al., medRxiv, 2020, 2020.2004.2016.20065920, https:\/\/doi.org\/10.1101\/2020.04.16.20065920.","DOI":"10.1101\/2020.04.16.20065920"},{"key":"10.1016\/j.nantod.2020.101051_bib188","doi-asserted-by":"crossref","unstructured":"A. Shamshirian, A. Hessami, K. Heydari, R. Alizadeh-Navaei, M.A. Ebrahimzadeh, G.W. Yip, et al., medRxiv, 2020, 2020.2004.2014.20065276, https:\/\/doi.org\/10.1101\/2020.04.14.20065276.","DOI":"10.1101\/2020.04.14.20065276"},{"key":"10.1016\/j.nantod.2020.101051_bib189","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104787","article-title":"The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro","volume":"178","author":"Caly","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.nantod.2020.101051_bib190","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1080\/13102818.2020.1775118","article-title":"Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view: antiviral levels are not likely attainable with known dosing regimens","volume":"34","author":"Momekov","year":"2020","journal-title":"Biotechnol. Biotechnol. Equip."},{"key":"10.1016\/j.nantod.2020.101051_bib191","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1513\/AnnalsATS.201307-231OC","article-title":"Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease","volume":"11","author":"Olivier","year":"2014","journal-title":"Ann. Am. Thorac. Soc."},{"key":"10.1016\/j.nantod.2020.101051_bib192","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ijpharm.2015.12.028","article-title":"Pulmonary delivery of tobramycin-loaded nanostructured lipid carriers for Pseudomonas aeruginosa infections associated with cystic fibrosis","volume":"498","author":"Moreno-Sastre","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.nantod.2020.101051_bib193","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S2213-2600(15)00245-3","article-title":"Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial","volume":"3","author":"Alton","year":"2015","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.nantod.2020.101051_bib194","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.nano.2012.11.001","article-title":"Development of a nanoparticle-based influenza vaccine using the PRINT\u00ae technology","volume":"9","author":"Galloway","year":"2013","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10.1016\/j.nantod.2020.101051_bib195","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1586\/1744666X.5.1.63","article-title":"Role of the pulmonary epithelium and inflammatory signals in acute lung injury","volume":"5","author":"Manicone","year":"2009","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.nantod.2020.101051_bib196","doi-asserted-by":"crossref","unstructured":"M. Zietz, N.P. Tatonetti, medRxiv, 2020, 2020.2004.2008.20058073, https:\/\/doi.org\/10.1101\/2020.04.08.20058073.","DOI":"10.1101\/2020.04.08.20058073"},{"key":"10.1016\/j.nantod.2020.101051_bib197","doi-asserted-by":"crossref","unstructured":"J. Zhao, Y. Yang, H. Huang, D. Li, D. Gu, X. Lu, et al., medRxiv, 2020, 2020.2003.2011.20031096, https:\/\/doi.org\/10.1101\/2020.03.11.20031096.","DOI":"10.1101\/2020.03.11.20031096"},{"key":"10.1016\/j.nantod.2020.101051_bib198","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/glycob\/cwn093","article-title":"Inhibition of the interaction between the SARS-CoV Spike protein and its cellular receptor by anti-histo-blood group antibodies","volume":"18","author":"Guillon","year":"2008","journal-title":"Glycobiology"},{"key":"10.1016\/j.nantod.2020.101051_bib199","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41385-020-0303-9","article-title":"Resistance of children to Covid-19. How","volume":"13","author":"Fischer","year":"2020","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.nantod.2020.101051_bib200","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1126\/science.abc3517","article-title":"Estimating the burden of SARS-CoV-2 in France","volume":"369","author":"Salje","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.nantod.2020.101051_bib201","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S2352-4642(20)30135-8","article-title":"The immune system of children: the key to understanding SARS-CoV-2 susceptibility","volume":"4","author":"Carsetti","year":"2020","journal-title":"Lancet Child Adolesc. Health"},{"key":"10.1016\/j.nantod.2020.101051_bib202","doi-asserted-by":"crossref","unstructured":"K.W. Ng, N. Faulkner, G.H. Cornish, A. Rosa, R. Harvey, S. Hussain, et al., bioRxiv, 2020, 2020.2005.2014.095414, https:\/\/doi.org\/10.1101\/2020.05.14.095414.","DOI":"10.1101\/2020.05.14.095414"},{"key":"10.1016\/j.nantod.2020.101051_bib203","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107725","article-title":"Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections","volume":"31","author":"Lv","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.nantod.2020.101051_bib204","first-page":"eabd3871","article-title":"Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans","author":"Mateus","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.nantod.2020.101051_bib205","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.08.017","article-title":"Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19","author":"Sekine","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.nantod.2020.101051_bib206","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","article-title":"Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals","volume":"181","author":"Grifoni","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.nantod.2020.101051_bib207","doi-asserted-by":"crossref","unstructured":"J. Braun, L. Loyal, M. Frentsch, D. Wendisch, P. Georg, F. Kurth, et al., medRxiv, 2020, 2020.2004.2017.20061440, https:\/\/doi.org\/10.1101\/2020.04.17.20061440.","DOI":"10.1101\/2020.04.17.20061440"},{"key":"10.1016\/j.nantod.2020.101051_bib208","doi-asserted-by":"crossref","unstructured":"N.L. Bert, A.T. Tan, K. Kunasegaran, C.Y.L. Tham, M. Hafezi, A. Chia, et al., bioRxiv, 2020, 2020.2005.2026.115832, https:\/\/doi.org\/10.1101\/2020.05.26.115832.","DOI":"10.1101\/2020.05.26.115832"},{"key":"10.1016\/j.nantod.2020.101051_bib209","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.3390\/v7041700","article-title":"Incorporation of spike and membrane glycoproteins into coronavirus virions","volume":"7","author":"Ujike","year":"2015","journal-title":"Viruses"}],"container-title":["Nano Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1748013220302218?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1748013220302218?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T20:17:01Z","timestamp":1761682621000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1748013220302218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":209,"alternative-id":["S1748013220302218"],"URL":"https:\/\/doi.org\/10.1016\/j.nantod.2020.101051","relation":{},"ISSN":["1748-0132"],"issn-type":[{"value":"1748-0132","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential immuno-nanomedicine strategies to fight COVID-19 like pulmonary infections","name":"articletitle","label":"Article Title"},{"value":"Nano Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nantod.2020.101051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101051"}}